DE69837274D1 - Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten - Google Patents

Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten

Info

Publication number
DE69837274D1
DE69837274D1 DE69837274T DE69837274T DE69837274D1 DE 69837274 D1 DE69837274 D1 DE 69837274D1 DE 69837274 T DE69837274 T DE 69837274T DE 69837274 T DE69837274 T DE 69837274T DE 69837274 D1 DE69837274 D1 DE 69837274D1
Authority
DE
Germany
Prior art keywords
nucleic acids
lipid
seculation
double layers
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837274T
Other languages
English (en)
Other versions
DE69837274T2 (de
Inventor
Edward G Saravolac
Yuan-Peng Zhang
Jeffery J Wheeler
Pieter R Cullis
Peter Scherrer
Ljiljana D Kojic
Olga Ludkovski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbutus Biopharma Corp
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of DE69837274D1 publication Critical patent/DE69837274D1/de
Application granted granted Critical
Publication of DE69837274T2 publication Critical patent/DE69837274T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69837274T 1997-10-10 1998-10-09 Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten Expired - Lifetime DE69837274T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6347397P 1997-10-10 1997-10-10
US63473P 1997-10-10
PCT/US1998/021500 WO1999018933A2 (en) 1997-10-10 1998-10-09 Methods for encapsulating nucleic acids in lipid bilayers

Publications (2)

Publication Number Publication Date
DE69837274D1 true DE69837274D1 (de) 2007-04-19
DE69837274T2 DE69837274T2 (de) 2007-11-08

Family

ID=22049444

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837274T Expired - Lifetime DE69837274T2 (de) 1997-10-10 1998-10-09 Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten

Country Status (6)

Country Link
EP (1) EP1023048B1 (de)
AT (1) ATE355826T1 (de)
AU (1) AU1360499A (de)
CA (2) CA2792406A1 (de)
DE (1) DE69837274T2 (de)
WO (1) WO1999018933A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1754488A1 (de) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
WO2001005373A1 (en) * 1999-07-15 2001-01-25 Inex Pharmaceuticals Corp. Methods and apparatus for preparation of lipid vesicles
US7094423B1 (en) 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
US6242188B1 (en) 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
WO2002014548A1 (en) * 2000-08-10 2002-02-21 Applied Gene Technologies, Inc. Compositions and methods for nucleic acids sample processing and amplification
KR100822684B1 (ko) 2000-10-04 2008-04-17 교와 핫꼬 고교 가부시끼가이샤 지질막에 의한 미립자의 피복방법
EP2823809B1 (de) 2002-06-28 2016-11-02 Protiva Biotherapeutics Inc. Verfahren und Vorrichtung zur Herstellung von Liposomen
EP2567693B1 (de) 2003-07-16 2015-10-21 Protiva Biotherapeutics Inc. Interferierende, in Lipiden eingekapselte RNA
JP4842821B2 (ja) 2003-09-15 2011-12-21 プロチバ バイオセラピューティクス インコーポレイティッド ポリエチレングリコール修飾脂質化合物およびその使用
WO2005121348A1 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2006053430A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
EP2125031B1 (de) * 2006-12-19 2017-11-01 Marina Biotech, Inc. Lipide und lipidanordnungen mit transfektionsverstärkungselementen
JP5674476B2 (ja) 2008-01-25 2015-02-25 ピー５３ インコーポレイテッド Ｐ５３バイオマーカー
PT2279254T (pt) 2008-04-15 2017-09-04 Protiva Biotherapeutics Inc Novas formulações lipídicas para entrega de ácido nucleico
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011056682A1 (en) 2009-10-27 2011-05-12 The University Of British Columbia Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
PT3338765T (pt) 2009-12-01 2019-03-18 Translate Bio Inc Derivado de esteróide adequado para a administração de arnm em doenças genéticas humanas
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
AU2012267531B2 (en) 2011-06-08 2017-06-22 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
KR102252561B1 (ko) 2013-11-22 2021-05-20 미나 테라퓨틱스 리미티드 Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
RU2620077C1 (ru) * 2015-11-26 2017-05-22 Ярославов А.А. Способ получения иммобилизованных бислойных везикул
EP3679138B1 (de) 2017-09-08 2023-03-22 MiNA Therapeutics Limited Hnf4a-sarna-zusammensetzungen und verfahren zur verwendung
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
US11566246B2 (en) 2018-04-12 2023-01-31 Mina Therapeutics Limited SIRT1-saRNA compositions and methods of use
US20220211740A1 (en) 2019-04-12 2022-07-07 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
US20240175033A1 (en) 2021-03-26 2024-05-30 Mina Therapeutics Limited TMEM173 saRNA Compositions and Methods of Use
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037194A1 (en) * 1995-05-26 1996-11-28 Somatix Therapy Corporation Delivery vehicles comprising stable lipid/nucleic acid complexes
EP0832271B8 (de) * 1995-06-07 2005-03-02 INEX Pharmaceuticals Corp. Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer

Also Published As

Publication number Publication date
WO1999018933A2 (en) 1999-04-22
CA2792406A1 (en) 1999-04-22
DE69837274T2 (de) 2007-11-08
AU1360499A (en) 1999-05-03
WO1999018933A3 (en) 1999-07-01
CA2309727C (en) 2012-12-04
CA2309727A1 (en) 1999-04-22
EP1023048A1 (de) 2000-08-02
ATE355826T1 (de) 2007-03-15
EP1023048B1 (de) 2007-03-07

Similar Documents

Publication Publication Date Title
DE69837274D1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
ATE316333T1 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
ATE209887T1 (de) Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
DE59510976D1 (de) Verfahren zur isolierung von zellinhaltsstoffen, wie nucleinsäuren, aus natürlichen quellen
DE60030970D1 (de) Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
DE69534669D1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
DE69736598D1 (de) Ribonukleaseresistente rna präparation und seine verwendung
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
AU4981101A (en) Subtilisin variants
ATE272393T1 (de) Rekonstruktion gereinigter membranproteine in vorgefertigten liposomen
AR020884A1 (es) Genes de enzimas modificadoras de acidos grasos vegetales asociadas con la formacion de dobles enlaces
NO20014231L (no) Innkapsling av bioaktive komplekser i liposomer
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
WO2003063785A3 (en) Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
AU2773695A (en) Compositions for and methods of enhancing delivery of nucleic acids to cells
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
HUT43106A (en) Dns sequences koding proteins of flesh-i type inhibitor activity and process for producing these proteins
BG101379A (en) New pypimido [1,2-a] indoles
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ATE353368T1 (de) Verfahren zur herstellung verzweigtkettiger fettsäuren mittels genetisch modifizierter pflanzen
DE69900653D1 (de) Verfahren zur Herstellung von Säuregruppen enthaltenden Bisxylenolen
FI20000956A0 (fi) Kosmeettinen tai ihonhoidollinen voidekoostumus, sen valmistusmenetelmä ja käyttö
WO2002074922A3 (en) Compositions and methods for modulating an immune response
WO1999059638A8 (en) Compositions and methods for the delivery of nucleic acid molecules
Cho et al. Isolation of Sunflower Seed Protein and its Chemical Composition

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: INEX PHARMACEUTICALS CORP., BURNABY, BRITISH C, CA

8327 Change in the person/name/address of the patent owner

Owner name: TEKMIRA PHARMACEUTICALS CORP., BURNABY, BRITIS, CA